Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T82668 Target Info
Target Name Kynurenine oxoglutarate transaminase II (AADAT)
Synonyms Kynurenineoxoglutarate transaminase II; Kynurenineoxoglutarate transaminase 2; Kynurenineoxoglutarate aminotransferase II; Kynurenine/alphaaminoadipate aminotransferase, mitochondrial; Kynurenine aminotransferase II; KAT/AadAT; Alphaaminoadipate aminotransferase; AadAT; 2aminoadipate transaminase; 2aminoadipate aminotransferase
Target Type Preclinical Target
Gene Name AADAT
Biochemical Class Transaminase
UniProt ID
AADAT_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US8933095
Title KAT II inhibitors
Abstract Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
Applicant(s) Pfizer Inc.
Representative Drug(s) D07JBL Drug Info IC50 = 59.4 nM Click to Show More [1]
2 D09JPJ Drug Info IC50 = 85 nM [1]
Patent ID US8933095
Title KAT II inhibitors
Abstract Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
Applicant(s) Pfizer Inc.
Representative Drug(s) D07JBL Drug Info IC50 = 59.4 nM Click to Show More [1]
2 D09JPJ Drug Info IC50 = 85 nM [1]
Patent ID US8598200
Title KAT II inhibitors
Abstract Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
Applicant(s) Pfizer Inc.
Representative Drug(s) D0SZ7H Drug Info IC50 = 24.3 nM Click to Show More [2]
2 D0RR5C Drug Info IC50 = 329 nM [2]
Patent ID US8598200
Title KAT II inhibitors
Abstract Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
Applicant(s) Pfizer Inc.
Representative Drug(s) D0SZ7H Drug Info IC50 = 24.3 nM Click to Show More [2]
2 D0RR5C Drug Info IC50 = 329 nM [2]
Patent ID US10065972
Title Bicyclic or tricyclic heterocyclic compound
Abstract The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom,X3 is a nitrogen atom, or CR2,X4 is a nitrogen atom, or CR3,X5 is a sulfur atom, or CHCH,Z1 is an oxygen atom, C(R6)(R7), NH, C(R6)(R7)NH, NHC(R6)(R7), C(R6)(R7)O, OC(R6)(R7), or a single bond,one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms,and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.
Applicant(s) MITSUBISHI TANABE PHARMA CORPORATION
Representative Drug(s) D03DSN Drug Info IC50 = 16 nM Click to Show More [3]
2 D08ETC Drug Info IC50 = 27 nM [3]
3 D0QE9Q Drug Info IC50 = 76 nM [3]
Patent ID US10065972
Title Bicyclic or tricyclic heterocyclic compound
Abstract The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom,X3 is a nitrogen atom, or CR2,X4 is a nitrogen atom, or CR3,X5 is a sulfur atom, or CHCH,Z1 is an oxygen atom, C(R6)(R7), NH, C(R6)(R7)NH, NHC(R6)(R7), C(R6)(R7)O, OC(R6)(R7), or a single bond,one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms,and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.
Applicant(s) MITSUBISHI TANABE PHARMA CORPORATION
Representative Drug(s) D03DSN Drug Info IC50 = 16 nM Click to Show More [3]
2 D08ETC Drug Info IC50 = 27 nM [3]
3 D0QE9Q Drug Info IC50 = 76 nM [3]
Patent ID US10065972
Title Bicyclic or tricyclic heterocyclic compound
Abstract The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom,X3 is a nitrogen atom, or CR2,X4 is a nitrogen atom, or CR3,X5 is a sulfur atom, or CHCH,Z1 is an oxygen atom, C(R6)(R7), NH, C(R6)(R7)NH, NHC(R6)(R7), C(R6)(R7)O, OC(R6)(R7), or a single bond,one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms,and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.
Applicant(s) MITSUBISHI TANABE PHARMA CORPORATION
Representative Drug(s) D03DSN Drug Info IC50 = 16 nM Click to Show More [3]
2 D08ETC Drug Info IC50 = 27 nM [3]
3 D0QE9Q Drug Info IC50 = 76 nM [3]
References  Top
REF 1 KAT II inhibitors. US8933095.
REF 2 KAT II inhibitors. US8598200.
REF 3 Bicyclic or tricyclic heterocyclic compound. US10065972.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.